Alva man says new kidney cancer drug’s vital in fight against disease, after his diagnosis
Written by centralfmnews on October 12, 2021
A new combined drug has been approved for use in Scotland to help treat advanced kidney cancer.
Cabometyx – a combination of cabozantinib and nivolimab – is expected to help 230 patients in Scotland each year.
The Scottish Medicines Consortium approved the medicine after trials found it can increase life expectancy by 10%.
Scotland is one of the first countries in the world to announce the use of the treatment – a decision welcomed by Ipsen UK.
Paul Dornan (61) from Alva has an incurable form of kidney cancer and is currently under palliative care, meaning he will not benefit from the drug.
However, he says developments like this are vital in the fight against cancer and explains how it will have an impact on more than just 230 people a year. He said:
“It’s not really 230 people, it’s 1-thousand or maybe 15-hundred people who are being affected.
“That’s 230 lives and it’s 230 families who have grandchildren like myself.”
Paul went to his doctor after passing a small amount of blood in his urine, something he wasn’t too worried about at first.
However, after his GP sent him for a scan, they found a tumour the size of a tennis ball which he quickly got removed.
Paul thought this was the end of his cancer journey and he’d had a lucky escape.
Unfortunately, Paul’s post-op scan showed a number of metastases in various locations and was confirmed as Chromophobe RCC.
Paul has been told by doctors that his treatment options have “effectively ran out” and is now under the palliative care team.
He’s now encouraging anyone who has any minor symptoms to get checked by their GP.
He tells us:
” I thought I’d just pulled a muscle and it went away, but if I’d went to my doctor then I might not have been having this conversation now because I would be totally cured.
“That three months might have been the period of time where the cancer developed that much that I was incurable, as it turned out.”